296 related articles for article (PubMed ID: 26873719)
1. Hereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic target.
Goyal G; Fan T; Silberstein PT
Fam Cancer; 2016 Jul; 15(3):359-66. PubMed ID: 26873719
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome.
Agarwal R; Liebe S; Turski ML; Vidwans SJ; Janku F; Garrido-Laguna I; Munoz J; Schwab R; Rodon J; Kurzrock R; Subbiah V;
Discov Med; 2014 Dec; 18(101):331-9. PubMed ID: 25549704
[TBL] [Abstract][Full Text] [Related]
3. Systemic therapy options in BRCA mutation-associated breast cancer.
Bayraktar S; Glück S
Breast Cancer Res Treat; 2012 Sep; 135(2):355-66. PubMed ID: 22791366
[TBL] [Abstract][Full Text] [Related]
4. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
5. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Turk AA; Wisinski KB
Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
[TBL] [Abstract][Full Text] [Related]
6. Evolution of cancer risk assessment and counseling related to psychological, financial and legal implications.
Snyder C
Fam Cancer; 2016 Jul; 15(3):493-6. PubMed ID: 26920353
[TBL] [Abstract][Full Text] [Related]
7. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
Cerrato A; Morra F; Celetti A
J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
[TBL] [Abstract][Full Text] [Related]
8. [BRCA1 and BRCA2 - pathologists starting kit].
Škapa P
Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
[TBL] [Abstract][Full Text] [Related]
9. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
10. [Hereditary breast and ovarian cancer syndrome: Diagnosis and therapeutic implications].
Koual M; Perkins G; Delanoy N; Crespel C; Medioni J; Nguyen-Xuan HT; Douay-Hauser N; Blons H; Le Frère-Belda MA; Molière D; Achen G; Nos C; Balaya V; Montero R; Laurent-Puig P; Bats AS
Ann Pathol; 2020 Apr; 40(2):70-77. PubMed ID: 32046878
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.
Oda K; Tanikawa M; Sone K; Mori-Uchino M; Osuga Y; Fujii T
Int J Clin Oncol; 2017 Aug; 22(4):611-618. PubMed ID: 28508305
[TBL] [Abstract][Full Text] [Related]
12. Leveraging DNA repair deficiency in gynecologic oncology.
Walsh CS; Hodeib M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):24-31. PubMed ID: 26694829
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
Tan DS; Kaye SB
Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149
[TBL] [Abstract][Full Text] [Related]
14. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
[TBL] [Abstract][Full Text] [Related]
15. Tissue-Specific Carcinogens as Soil to Seed BRCA1/2-Mutant Hereditary Cancers.
Singh AK; Yu X
Trends Cancer; 2020 Jul; 6(7):559-568. PubMed ID: 32336659
[TBL] [Abstract][Full Text] [Related]
16. Defective DNA repair in hereditary ovarian cancers: Implications for therapy.
Burgess BT; Kolesar JM
Am J Health Syst Pharm; 2018 Nov; 75(21):1697-1707. PubMed ID: 30228165
[TBL] [Abstract][Full Text] [Related]
17. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic exploitation of tumor cell defects in homologous recombination.
Powell SN; Kachnic LA
Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
[TBL] [Abstract][Full Text] [Related]
19. The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1).
Sorscher S; Ansley K; Delaney SD; Ramkissoon S
Breast Cancer Res Treat; 2020 Apr; 180(2):511-514. PubMed ID: 32040686
[TBL] [Abstract][Full Text] [Related]
20. BRCA1/2 testing: therapeutic implications for breast cancer management.
Tung NM; Garber JE
Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]